Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of September 2019. The report serves as a transaction notification regarding a specific event involving a Person Discharging Managerial Responsibilities (PDMR) under the UK Market Abuse Regulation.
Key Financial Metrics
The filing does not provide consolidated financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics for the company. It reports a single executive compensation transaction:
- Transaction Type: Cash payment following the vesting of a Deferred Investment Award.
- Executive: Ms. Emma Walmsley, Chief Executive Officer.
- Instrument: Ordinary shares of 25 pence each (ISIN: GB0009252882).
- Volume: 10,667.982 notional Ordinary Shares.
- Price: £16.8580 per share.
- Gross Value: £179,840.84 (subject to applicable tax withholding).
Material Changes
The filing does not disclose material changes to the company's financial position, operations, or strategy compared to prior periods. The only reported change is the specific vesting event for the CEO's deferred investment award on September 23, 2019.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, outlook, risk factors, or discussion of contingencies. It is strictly a regulatory disclosure of a share-based compensation settlement.
Key Facts for Investor Verification
- Verify the vesting schedule and terms of the GlaxoSmithKline Deferred Investment Award Plan referenced in the transaction.
- Confirm the tax withholding implications for the £179,840.84 gross payment to the CEO.
- Note that this filing does not reflect the company's broader financial performance for the quarter or year.